• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Symic Bio Announces Closing of Investment led by CIP firstwordpharma
    April 26, 2019
    SAN FRANCISCO, April 25, 2019 /PRNewswire/ -- Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced the closing of financings led by Cell Innovation Partners (CIP) ...
  • Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 americanpharmaceuticalreview
    August 24, 2017
    Symic Bio announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061 for pain management in mild-to-moderate osteoarthritis of the knee.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service